Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Logomix Inc. maintains a focused presence in the Biotechnology & Pharmaceuticals technology area with 1 pending office action currently requiring attention. This 1 pending office action represents the entirety of the portfolio's active prosecution at this stage. The work is distributed across 1 distinct art unit, which points to a specialized application of the biological or pharmaceutical innovations. This concentration suggests that the company is prioritizing a specific technical niche rather than a broad-based filing strategy across multiple biotech disciplines.
The portfolio's examination is overseen by 1 distinct examiner, creating a streamlined interaction with the patent office. RAHMAN, MASUDUR is identified as the busiest examiner, holding responsibility for the 1 pending office action. This indicates that the company's immediate patenting success is tied to the specific requirements and interpretations of this official. For practitioners, this means that the prosecution strategy does not need to account for varying examiner temperaments or conflicting art unit guidelines.
Because the busiest examiner pending count is 1, there is no overlap or secondary prosecution path currently active. This structure suggests a deliberate and singular approach to securing intellectual property rights. The reliance on 1 distinct examiner and 1 distinct art unit minimizes administrative complexity but increases the importance of the upcoming response to the pending action. The strategy appears to favor precision within the biotechnology sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAHMAN, MASUDUR | 1 | 72.7% | +31.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18280103 | METHOD OF MODIFYING GENOMIC DNA AND METHOD OF DETECTING MODIFICATION | RAHMAN, MASUDUR | 46d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18280103 | METHOD OF MODIFYING GENOMIC DNA AND METHOD OF DETECTING MODIFICATION | RAHMAN, MASUDUR | 46d |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18280103 | METHOD OF MODIFYING GENOMIC DNA AND METHOD OF DETECTING MODIFICATION | RAHMAN, MASUDUR | 1633 | §102§103 | Final Rejection | 46d | Pending | Sep 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial